These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6168866)

  • 1. Endocrine and metabolic effects of labetalol in man.
    Barbieri C; Ferrari C; Caldara R; Crossignani RM; Bertazzoni A
    J Cardiovasc Pharmacol; 1981; 3(5):986-91. PubMed ID: 6168866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of labetalol on plasma catecholamines at rest and during increased sympathetic activity.
    Carlsen JE; Trap-Jensen J; Svendsen TL; Nielsen PE; Rasmussen S; Christensen NJ
    Postgrad Med J; 1980; 56 Suppl 2():43-8. PubMed ID: 7433342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological effects of labetalol in man.
    Richards DA
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):721-3. PubMed ID: 10949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.
    Lunell NO; Hjemdahl P; Fredholm BB; Nisell H; Persson B; Wager J
    Br J Clin Pharmacol; 1981 Sep; 12(3):345-8. PubMed ID: 7295464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of combined alpha-beta-blockade. I.
    Louis WJ; McNeil JJ; Drummer OH
    Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent antagonism of isoproterenol and norepinephrine after labetalol.
    Richards DA; Prichard BN
    Clin Pharmacol Ther; 1978 Mar; 23(3):253-8. PubMed ID: 627129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.
    Richards DA; Tuckman J; Prichard BN
    Br J Clin Pharmacol; 1976 Oct; 3(5):849-55. PubMed ID: 9968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodynamic and metabolic effects of combined adrenergic alpha- and beta-receptor blockade with labetalol in the exercising human forearm.
    Hartling OJ; Svendsen TL; Trap-Jensen J
    Eur J Clin Invest; 1980 Dec; 10(6):431-5. PubMed ID: 6265221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
    Elliott HL; McLean K; Meredith PA; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1984 May; 17(5):565-72. PubMed ID: 6145440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man.
    Riddell JG; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1985 Apr; 19(4):405-10. PubMed ID: 2859871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationships between the cardiovascular effects, alpha- and beta-adrenoceptor blocking actions and plasma concentration of labetalol in doca hypertensive rats.
    Drew GM; Hilditch A; Levy GP
    Clin Exp Hypertens (1978); 1979; 1(5):597-611. PubMed ID: 42517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between plasma concentrations and pharmacological effects of labetalol.
    Richards DA; Maconochie JG; Bland RE; Hopkins R; Woodings EP; Martin LE
    Eur J Clin Pharmacol; 1977 Jan; 11(2):85-90. PubMed ID: 14010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man.
    Christensen NJ; Trap-Jensen J; Svendsen TL; Rasmussen S; Nielsen PE
    Eur J Clin Pharmacol; 1978 Dec; 14(4):227-30. PubMed ID: 365539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological basis for antihypertensive effects of intravenous labetalol.
    Richards DA; Prichard BN; Boakes AJ; Tuckman J; Knight EJ
    Br Heart J; 1977 Jan; 39(1):99-106. PubMed ID: 12778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The response of plasma catecholamines to intravenous labetalol: a comparison with sodium nitroprusside.
    Lin MS; McNay JL; Shepherd AM; Keeton TK
    Clin Pharmacol Ther; 1983 Oct; 34(4):466-73. PubMed ID: 6617068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attempted reduction of the cardiostimulatory effects of ketamine by labetalol.
    Dundee JW; Lilburn JK; Moore J
    Anaesthesia; 1978 Jun; 33(6):506-11. PubMed ID: 686309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the haemodynamic effects of labetalol in man.
    Cohn JN; Mehta J; Francis GS
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):19S-26S. PubMed ID: 7093099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.
    Lammintausta R; Koulu M; Allonen H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):240-43. PubMed ID: 38214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.
    Trust PM; Rosei EA; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):799-803. PubMed ID: 791333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-hypertensive action, time of onset and effects on carbohydrate metabolism of labetalol.
    Andersson O; Berglund G; Hansson L
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):757-61. PubMed ID: 1032990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.